PDL BioPharma Current Ratio 2010-2020 | PDLI

PDL BioPharma current ratio from 2010 to 2020. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
PDL BioPharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2020-12-31 $0.00B 0.00
2020-06-30 $0.50B $0.04B 13.68
2020-03-31 $0.55B $0.04B 13.21
2019-12-31 $0.31B $0.05B 6.87
2019-09-30 $0.41B $0.04B 9.94
2019-06-30 $0.40B $0.04B 10.43
2019-03-31 $0.48B $0.04B 11.02
2018-12-31 $0.52B $0.05B 9.86
2018-09-30 $0.51B $0.05B 10.88
2018-06-30 $0.51B $0.05B 11.13
2018-03-31 $0.51B $0.05B 10.03
2017-12-31 $0.64B $0.19B 3.32
2017-09-30 $0.61B $0.19B 3.16
2017-06-30 $0.54B $0.28B 1.94
2017-03-31 $0.54B $0.28B 1.98
2016-12-31 $0.40B $0.13B 3.05
2016-09-30 $0.36B $0.12B 2.92
2016-06-30 $0.32B $0.02B 14.19
2016-03-31 $0.38B $0.03B 13.04
2015-12-31 $0.28B $0.04B 7.70
2015-09-30 $0.31B $0.10B 3.24
2015-06-30 $0.37B $0.14B 2.55
2015-03-31 $0.50B $0.34B 1.46
2014-12-31 $0.36B $0.19B 1.89
2014-09-30 $0.34B $0.26B 1.31
2014-06-30 $0.23B $0.31B 0.75
2014-03-31 $0.36B $0.35B 1.03
2013-12-31 $0.11B $0.41B 0.26
2013-09-30 $0.33B $0.21B 1.59
2013-06-30 $0.28B $0.24B 1.20
2013-03-31 $0.26B $0.07B 3.76
2012-12-31 $0.18B $0.01B 17.47
2012-09-30 $0.20B $0.03B 6.28
2012-06-30 $0.24B $0.09B 2.56
2012-03-31 $0.21B $0.15B 1.38
2011-12-31 $0.23B $0.13B 1.76
2011-09-30 $0.22B $0.17B 1.26
2011-06-30 $0.21B $0.22B 0.98
2011-03-31 $0.19B $0.35B 0.53
2010-12-31 $0.29B $0.19B 1.47
2010-09-30 $0.24B $0.21B 1.13
2010-06-30 $0.24B $0.31B 0.78
2010-03-31 $0.33B $0.42B 0.80
2009-12-31 $0.32B $0.29B 1.08
2009-09-30 $0.25B $0.27B 0.94
2009-06-30 $0.21B $0.07B 3.07
2009-03-31 $0.21B $0.13B 1.61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.000B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00